LifeSci Capital Maintains Buy Rating on Tenax Therapeutics with $35 Price Target
核心洞察
LifeSci Capital analyst Gaurav Maini reiterated a Buy rating on Tenax Therapeutics (TENX) with a $35.00 price target.
The broader analyst consensus rates Tenax Therapeutics as a Strong Buy with an average price target of $37.40.
Tenax Therapeutics reported a GAAP net loss of $15.72 million for the quarter ending March 31, compared to a $10.41 million loss in the prior-year period.
LifeSci Capital analyst Gaurav Maini has reaffirmed a Buy rating on Tenax Therapeutics (TENX), setting a price target of $35.00, according to a report released today. The endorsement comes as the broader analyst community maintains a bullish outlook on the clinical-stage pharmaceutical company.
The consensus on Wall Street points to a Strong Buy rating for Tenax Therapeutics, with an average price target of $37.40 across covering analysts. Maini, who focuses on the healthcare sector and also covers Tectonic Therapeutic and Inhibikase Therapeutics, carries a 4-star rating on TipRanks, reflecting an average return of 30.8% and a 100% success rate on his recommendations.
On the financial front, Tenax Therapeutics reported a GAAP net loss of $15.72 million for the quarter ending March 31, widening from a net loss of $10.41 million in the same period last year. The increased loss reflects the company's ongoing investment in its clinical development pipeline as it advances its therapeutic candidates toward key milestones.